DEFA14A ·Filed Apr 20, 2026

NVCR

NovoCure Ltd
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001645113-26-000034
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine annual proxy filing. Monitor for any unexpected outcomes in the shareholder vote, though none are anticipated given the lack of dissident activity. The recent executive compensation change noted in the 8-K is the only notable event.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NVCR ▲ +34.26% at T+60d
NEUTRAL call ✓ call won +34.26% · α vs SPY +27.36% · entry $12.23 → $16.42
Entry anchored
Apr 20, 03:59 PM ET
via exchange tick
T+1d
+6.46%
call +6.46% · α +5.44%
$13.02
settled 5mo ago
T+5d
-0.90%
call -0.90% · α -1.98%
$12.12
settled 5mo ago
T+20d
+42.76%
call +42.76% · α +37.85%
$17.46
settled 5mo ago
T+60d
+34.26%
call +34.26% · α +27.36%
$16.42
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

NovoCure's DEFA14A filing is a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amended incentive plan. This follows recent board changes, suggesting the vote is routine. The filing is neutral with low impact.

Key Facts

  • Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • Shareholders will vote on 11 director nominees, auditor ratification, executive compensation, and an amended incentive plan.
  • Recent 8-K filing (11 days prior) reported a compensation change for an executive officer.
  • No activist campaign or dissident slate is present; this is a management solicitation.

Financial Impact

No direct financial impact from the proxy filing itself.

executive compensationgovernance

Risk Factors

  • Low risk of shareholder revolt on any proposal, as is typical for routine management solicitations.
  • Potential for minor governance concerns if any director nominee faces significant opposition, though none is indicated.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001645113-26-000034
Document: 0001645113-26-000034-index-headers.html0001645113-26-000034
Document: 0001645113-26-000034-index.html0001645113-26-000034
Document: 0001645113-26-000034.txt0001645113-26-000034
14 reports for NVCR
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+20▲ +19.75%Feb 27, 2026
Filters
Rows
Reports for NVCR — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
8-K
NEUTRAL ★ 2/10
$15.63 $16.38▲ +4.80%▲ +5.13%$14.94 (−4.41%)
Sep 1, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$17.38 $15.63▼ −10.07%▼ −10.15%$14.94 (−14.04%)
Jul 23, 2026
10w ago
8-K
BULLISH ★ 7/10
$19.99 $15.23▼ −23.81%▼ −24.29%$14.94 (−25.26%)
Jun 30, 2026
13w ago
8-K
BULLISH ★ 7/10
$15.15 $17.32▲ +14.32%▲ +13.72%$14.94 (−1.39%)
Jun 18, 2026
15w ago
8-K
BEARISH ★ 6/10
$14.28 $15.05▼ −5.39%▼ −7.06%$14.94 (−4.62%)
Jun 5, 2026
17w ago
8-K
NEUTRAL ★ 4/10
$16.85 $17.60▲ +4.45%▲ +2.34%$14.94 (−11.34%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.99 $17.71▼ −1.56%▲ +1.00%$14.94 (−16.95%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.99 $17.71▼ −1.56%▲ +1.00%$14.94 (−16.95%)
Apr 20, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$12.23 $12.12▼ −0.90%▼ −1.98%$14.94 (+22.16%)
Feb 27, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$13.67 $13.04▼ −4.61%▼ −2.63%$14.94 (+9.29%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (65h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access